Effects of AZD5004 in adults who are living with obesity or overweight with at least 1 weight-related comorbidity - VISTA

Study identifier:D7260C00001

ClinicalTrials.gov identifier:NCT06579092

EudraCT identifier:N/A

CTIS identifier:2024-513691-18-00

Will Be Recruiting

Official Title

A Phase IIb Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD5004 in Participants Living with Obesity or Overweight with Comorbidity

Medical condition

Obesity or Overweight

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD5004, Placebo

Sex

All

Estimated Enrollment

285

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 01 Oct 2024
Estimated Primary Completion Date: 09 Dec 2025
Estimated Study Completion Date: 09 Dec 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria